AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9645457 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (0.5 mg i.v. bolus + continuous infusion of 0.04 mg/h for 7 days)
Number of subjects: 48
Study 9645457 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (8 mg i.v. bolus + continuous infusion of 1 mg/h for 7 days)
Number of subjects: 48
Study 8174846 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP (0.04 micrograms.kg‐1.min‐1)
Number of subjects: 22
Study 8174846 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (50 ml saline)
Number of subjects: 22
Study 3237194 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion (3,680 mIU in 45 min)
Number of subjects: 20
Study 30665386 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes or hypertension
Number of subjects: 1609
Study 30665386 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents in rural Walungu health zone
Number of subjects: 1609
Study 30665386 — intervention group
Group type: EXPERIMENTAL
Intervention: Female respondents
Number of subjects: 1609
Study 30665386 — intervention group
Group type: EXPERIMENTAL
Intervention: Older respondents
Number of subjects: 1609
Study 30665386 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondents from the poorest socioeconomic status
Number of subjects: 1609
Study 30665386 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondents who had an acute illness 30 days prior to the interview
Number of subjects: 1609
Study 30665386 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondents who are informally employed
Number of subjects: 1609
Study 30665386 — intervention group
Group type: EXPERIMENTAL
Intervention: Petty traders/farmers
Number of subjects: 1609
Study 29781459 — intervention group
Group type: EXPERIMENTAL
Intervention: FCG support intervention
Number of subjects: 20
Study 27429596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-workout supplement (SUP)
Number of subjects: 13
Study 27429596 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 13
Study 27429596 — intervention group
Group type: COMPARATOR
Intervention: Baseline (BA)
Number of subjects: 13
Study 24550162 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle aspiration (FNA)
Number of subjects: 32
Study 24550162 — intervention group
Group type: COMPARATOR
Intervention: EUS-guided core biopsy needle (FNB)
Number of subjects: 32
Study 21300729 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumiced for 10 seconds and pre-etched for 5 seconds with 37% phosphoric acid before bonding with SEP (Transbond Plus)
Number of subjects: 60
Study 21300729 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumiced for 10 seconds before bonding
Number of subjects: 60
Study 21300729 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-etched for 5 seconds before bonding
Number of subjects: 60
Study 21300729 — intervention group
Group type: COMPARATOR
Intervention: No mechanical or chemical preparation before bonding
Number of subjects: 60
Study 19114685 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab added to bevacizumab and chemotherapy (oxaliplatin-based)
Number of subjects: 1053
Study 19114685 — intervention group
Group type: COMPARATOR
Intervention: Control (bevacizumab and chemotherapy without panitumumab)
Number of subjects: 1053
Study 19114685 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab added to bevacizumab and chemotherapy (irinotecan-based)
Number of subjects: 1053
Study 17709802 — intervention group
Group type: EXPERIMENTAL
Intervention: HDC/IL-2/IFN
Number of subjects: 241
Study 17709802 — intervention group
Group type: COMPARATOR
Intervention: DTIC
Number of subjects: 241
Study 15990651 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fibrin tissue adhesive
Number of subjects: 39
Study 15990651 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin tissue adhesive)
Number of subjects: 39
Study 15990651 — intervention group
Group type: COMPARATOR
Intervention: Commercial fibrin tissue adhesive
Number of subjects: 39
Study 12063437 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin treatment for patients with antiphospholipid antibodies
Number of subjects: 0
Study 12063437 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoimmune factors as markers
Number of subjects: 0
Study 9676903 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithelial removal followed by excimer laser ablation
Number of subjects: 56
Study 9676903 — intervention group
Group type: COMPARATOR
Intervention: Epithelial removal only
Number of subjects: 56
Study 10150265 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% bromochlorophene toothpaste
Number of subjects: 32
Study 10150265 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 32
Study 10150265 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BCP and placebo toothpastes
Number of subjects: 32
Study 3291523 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion therapy (CSII)
Number of subjects: 12
Study 3291523 — intervention group
Group type: COMPARATOR
Intervention: Insulin injection therapy
Number of subjects: 12
Study 8022437 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (2 mg, 4 ml)
Number of subjects: 54
Study 8022437 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 ml nebulized normal saline)
Number of subjects: 54
Study 8022437 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide
Number of subjects: 54
Study 8022437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 371664 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg prostaglandin E2 (PGE2)
Number of subjects: 0
Study 371664 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg prostaglandin F2 alpha (PGF2 alpha)
Number of subjects: 0
Study 371664 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31799875 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 39
Study 31608829 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete sleep deprivation (DEP)
Number of subjects: 10
Study 31608829 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (PART)
Number of subjects: 10
Study 31608829 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep (CON)
Number of subjects: 10
Study 28131004 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate health benefits information
Number of subjects: 110
Study 28131004 — intervention group
Group type: COMPARATOR
Intervention: Long-term health benefits information
Number of subjects: 110
Study 25552408 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight
Number of subjects: 0
Study 23980808 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 2349
Study 21861914 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV + PR
Number of subjects: 66
Study 21861914 — intervention group
Group type: COMPARATOR
Intervention: PR
Number of subjects: 66
Study 19482279 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mm Zilver stent
Number of subjects: 241
Study 19482279 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mm Zilver stent
Number of subjects: 241
Study 19482279 — intervention group
Group type: COMPARATOR
Intervention: 10-mm Wallstent
Number of subjects: 241
Study 17223872 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment
Number of subjects: 9
Study 17223872 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone butyrate ointment
Number of subjects: 9
Study 15643131 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg daily for 16 weeks
Number of subjects: 49
Study 15643131 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg daily for 16 weeks
Number of subjects: 49
Study 15643131 — intervention group
Group type: COMPARATOR
Intervention: Healthy age- and sex-matched controls (n = 32)
Number of subjects: 49
Study 11881123 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg once-daily
Number of subjects: 15
Study 11881123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9562277 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfeel (occlusive dressing)
Number of subjects: 73
Study 9562277 — intervention group
Group type: COMPARATOR
Intervention: Mepore (conventional dressing)
Number of subjects: 73
Study 8173308 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% long-chain triglyceride emulsion
Number of subjects: 29
Study 8173308 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% medium-chain triglyceride emulsion
Number of subjects: 29
Study 8173308 — intervention group
Group type: COMPARATOR
Intervention: 20% glucose infusion
Number of subjects: 29
Study 8173308 — intervention group
Group type: COMPARATOR
Intervention: 10% long-chain triglyceride emulsion
Number of subjects: 29
Study 8173308 — intervention group
Group type: COMPARATOR
Intervention: 10% medium-chain triglyceride emulsion
Number of subjects: 29
Study 8173308 — intervention group
Group type: EXPERIMENTAL
Intervention: 150% of calculated daily calorie intake
Number of subjects: 29
Study 10312366 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous estrogens
Number of subjects: 0
Study 10312366 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 0
Study 31996604 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior TBI
Number of subjects: 1148
Study 31996604 — intervention group
Group type: COMPARATOR
Intervention: No prior TBI
Number of subjects: 1148
Study 30618101 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg misoprostol
Number of subjects: 453
Study 30618101 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg misoprostol
Number of subjects: 453
Study 30618101 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 μg misoprostol
Number of subjects: 453
Study 28783372 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with 2% lavender essential oil for 70 minutes every other week for 20 weeks (10 times total)
Number of subjects: 52
Study 28783372 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care (Control)
Number of subjects: 52
Study 28783372 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with 2% lavender essential oil
Number of subjects: 52
Study 28783372 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 52
Study 26067435 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment matching the biomarker indication
Number of subjects: 30
Study 26067435 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment mismatching the biomarker indication
Number of subjects: 30
Study 22528470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT) program
Number of subjects: 223
Study 22528470 — intervention group
Group type: COMPARATOR
Intervention: Health-related educational lectures (Control)
Number of subjects: 223
Study 22254084 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient fortified yogurt with additional probiotic Lactobacillus rhamnosus GR‐1
Number of subjects: 112
Study 22254084 — intervention group
Group type: COMPARATOR
Intervention: Micronutrient fortified yogurt without additional probiotic
Number of subjects: 112
Study 22254084 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (micronutrient yogurt with and without probiotics)
Number of subjects: 112
Study 19344858 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 0
Study 19344858 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 16856776 — intervention group
Group type: EXPERIMENTAL
Intervention: FluMist immunizations
Number of subjects: 0
Study 16856776 — intervention group
Group type: COMPARATOR
Intervention: Control (no FluMist immunizations)
Number of subjects: 0
Study 12885805 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose IFNalpha2b (3 million international units [MU]/m2/d, days 1 to 7, week 1; three times weekly, weeks 3 to 6, repeated all 6 weeks) plus IL-2 (9 MU/m2/d, days 1 to 4, week 2 of each cycle) for 48 weeks
Number of subjects: 225
Study 12885805 — intervention group
Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 225
Study 12885805 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose IFNalpha2b plus IL-2
Number of subjects: 225
Study 9890581 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonviolent criminal victimization
Number of subjects: 331
Study 9890581 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent criminal victimization
Number of subjects: 331
Study 9890581 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use and transient living conditions
Number of subjects: 331
Study 9890581 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived vulnerability to victimization
Number of subjects: 331
Study 8983921 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise test at 10 a.m.
Number of subjects: 15
Study 8983921 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise test at 5 p.m.
Number of subjects: 15
Study 1664869 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3; alkaline), dosage: 0.3 g kg‐1 body mass, 2.5 h prior to exercise
Number of subjects: 7
Study 1664869 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (NaCl; placebo), dosage: 1.5 g total, 2.5 h prior to exercise
Number of subjects: 7
Study 7208632 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric tonic neck reflex with active head rotation toward the extending wrist
Number of subjects: 150
Study 7208632 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric tonic neck reflex with active head rotation away from the extending wrist
Number of subjects: 150
Study 7208632 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency muscle vibration with head in neutral position
Number of subjects: 150
Study 7208632 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of active head rotation toward the extending wrist and vibration of the extensor surface
Number of subjects: 150
Study 7208632 — intervention group
Group type: COMPARATOR
Intervention: Control groups (fatigue, experimental learning, weight of vibrator)
Number of subjects: 150
Study 30213747 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-specific response inhibition training (active group)
Number of subjects: 41
Study 30213747 — intervention group
Group type: COMPARATOR
Intervention: Response inhibition training without food stimuli (control group)
Number of subjects: 41
Study 26652904 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17β‐estradiol (tE2)
Number of subjects: 79
Study 26652904 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (oCEE)
Number of subjects: 79
Study 26652904 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 79
Study 24661479 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic suggestion (TS)
Number of subjects: 94
Study 24661479 — intervention group
Group type: COMPARATOR
Intervention: Noise recordings (Control)
Number of subjects: 94
Study 22664557 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive training curriculum for laparoscopic colorectal surgery
Number of subjects: 25
Study 22664557 — intervention group
Group type: COMPARATOR
Intervention: Conventional residency training
Number of subjects: 25
Study 19675958 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy
Number of subjects: 34
Study 18587579 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus etoposide
Number of subjects: 47
Study 18587579 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion etoposide
Number of subjects: 47
Study 18587579 — intervention group
Group type: EXPERIMENTAL
Intervention: CEMP regimen (cisplatinum, etoposide, mitoxantrone, prednisone)
Number of subjects: 47
Study 15770198 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated image fusion method for repositioning error detection
Number of subjects: 8
Study 15770198 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scans of patients
Number of subjects: 8
Study 12458394 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-stimulated myocardial glucose uptake measured during hyperinsulinaemic euglycaemic glucose clamp with fluorine‐18 fluorodeoxyglucose.
Number of subjects: 20
Study 12458394 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-stimulated myocardial glucose uptake and blood flow at rest.
Number of subjects: 20
Study 12458394 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-stimulated myocardial glucose uptake.
Number of subjects: 20
Study 12458394 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial glucose uptake and hyperaemic blood flow.
Number of subjects: 20
Study 10362195 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (mean dosage 74±23 mg/day)
Number of subjects: 30
Study 10362195 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (mean dosage 142±44 mg/day)
Number of subjects: 30
Study 7557850 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) alfa therapy
Number of subjects: 141
Study 2026838 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-teaching booklets
Number of subjects: 161
Study 2026838 — intervention group
Group type: COMPARATOR
Intervention: Computer media
Number of subjects: 161
Study 2026838 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture format
Number of subjects: 161
Study 2026838 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-teaching booklet
Number of subjects: 161
Study 7025260 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenbufen (Cinopal; Lederle) and reduction in training activity
Number of subjects: 0
Study 7025260 — intervention group
Group type: COMPARATOR
Intervention: Reduction in training activity alone
Number of subjects: 0
Study 30689293 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow brace during repetitive pitching
Number of subjects: 25
Study 30689293 — intervention group
Group type: COMPARATOR
Intervention: No elbow brace (control)
Number of subjects: 25
Study 27793071 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-games self-training
Number of subjects: 24
Study 27793071 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional self-training
Number of subjects: 24
Study 27436663 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 676
Study 27436663 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K Antagonists (VKAs)
Number of subjects: 676
Study 24315724 — intervention group
Group type: EXPERIMENTAL
Intervention: New oral anticoagulants
Number of subjects: 71683
Study 24315724 — intervention group
Group type: EXPERIMENTAL
Intervention: New oral anticoagulants (low-dose)
Number of subjects: 71683
Study 23130740 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care delivered by an existing HIV facility nurse trained to a set standard
Number of subjects: 0
Study 23130740 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV care alone
Number of subjects: 0
Study 20674489 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 18
Study 20674489 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study 17347447 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 29
Study 17347447 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 29
Study 17347447 — intervention group
Group type: COMPARATOR
Intervention: Control group (CF patients without stop mutations)
Number of subjects: 29
Study 16263866 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD treatment for peacekeepers
Number of subjects: 129
Study 16263866 — intervention group
Group type: COMPARATOR
Intervention: PTSD treatment for Vietnam veterans
Number of subjects: 129
Study 12198002 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron bis-glycine chelate
Number of subjects: 85
Study 12198002 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron bis-glycine chelate (encapsulated in enteric gelatin capsules)
Number of subjects: 85
Study 12198002 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate
Number of subjects: 85
Study 12198002 — intervention group
Group type: COMPARATOR
Intervention: Heme iron
Number of subjects: 85
Study 10195718 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple extirpation of the hernial sac (Study A)
Number of subjects: 132
Study 10195718 — intervention group
Group type: COMPARATOR
Intervention: Extirpation plus annulorrhaphy (Study A)
Number of subjects: 132
Study 10195718 — intervention group
Group type: EXPERIMENTAL
Intervention: Extirpation plus annulorrhaphy (Study B)
Number of subjects: 132
Study 10195718 — intervention group
Group type: COMPARATOR
Intervention: Extirpation plus Lichtenstein mesh repair (modified) (Study B)
Number of subjects: 132
Study 10195718 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative pain scores during coughing and mobilization
Number of subjects: 132
Study 1592527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin C (MMC) with 60-min dwelling time
Number of subjects: 56
Study 1592527 — intervention group
Group type: COMPARATOR
Intervention: Intravesical mitomycin C (MMC) with 30-min dwelling time
Number of subjects: 56
Study 1592527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin C (MMC)
Number of subjects: 56
Study 4096193 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia supplemented with nitrous oxide
Number of subjects: 18
Study 4096193 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia combining fentanyl and continuous infusion of etomidate
Number of subjects: 18
Study 31479082 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsymptom threshold exercise program
Number of subjects: 0
Study 31479082 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care treatment (control)
Number of subjects: 0
Study 29975083 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery-oriented bibliotherapy program (book club)
Number of subjects: 26
Study 29975083 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study 27105563 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose adult formulation
Number of subjects: 209
Study 27105563 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose paediatric formulation
Number of subjects: 209